Synthekine il2
WebApr 10, 2024 · Synthekine Inc., an engineered cytokine therapeutics company, announced preclinical data presented at the American Association of Cancer Research Annual Meeting 2024 demonstrating its alpha/beta selective IL-2 partial agonist, STK-012, induced potent anti-tumor activity while avoiding the toxicities that have hindered the development of IL-2 … WebJun 10, 2024 · Nine months after launching out of Stanford with $82 million and a portfolio of engineered cytokines, Synthekine has landed a $107.5 million Series B from Deerfield Management and others to push ...
Synthekine il2
Did you know?
WebTreatment of Jurkat cells with a commercial phosphatase inhibitor NSC87877 which can impact many phosphatases resulted in immune activation, measured by increased IL2 levels, only in the presence of LAG3. When NSC87877 was combined with the PD1 antibody, it could phenocopy combination benefit of PD1 and LAG3 blocking antibodies. WebSynthekine will evaluate STK-012 in a Phase 1a/1b, open-label, multi-center, dose escalation study. The study will investigate STK-012 both as a monotherapy and in combination with an immune checkpoint inhibitor in individuals with advanced solid tumors. “IL-2 is a cytokine with proven benefit as an anti-cancer therapy.
WebLighting up only the immune cells that matter Asher Bio WebSep 7, 2024 · Despite the challenges, there's still plenty of interest in IL-2 as a cancer therapy, with several companies, including Medicenna, Anaveon, Cue Biopharma, Aulos Bioscience, and Synthekine in ...
WebThe source of the report is Plainvew LLC, which acknowledges it has a short position in Nektar, but analyst Aaron Wedlund is adamant that the biotech’s long-acting interleukin-2 (IL-2) candidate ... WebFeb 3, 2024 · MENLO PARK, Calif.--(BUSINESS WIRE)-- Synthekine., an engineered cytokine therapeutics company, today announced the dosing of the first patient in a Phase 1a/1b clinical trial of its IL-2 partial agonist, STK-012, for the treatment of solid tumors.STK-012 is designed as an alpha/beta-biased IL-2 partial agonist to selectively stimulate antigen …
WebDiscovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.
WebSynthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate ... black flat for womenWebOct 28, 2024 · MENLO PARK, Calif., October 28, 2024--Synthekine Inc., an engineered cytokine therapeutics company, today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). game of affection 44WebTo accomplish that, we have developed three distinct protein engineering platforms at Synthekine. ... IL10/IL2 Surrogate Cytokine Agonists. 2024 – AACR. IL-2Rβ/IL-2Rλ Synthetic Cytokines Induce Activation of Human T and NK Cells. 2024 – AACR. Facile discovery of surrogate cytokine agonists. black flathead wood screwsWebOct 28, 2024 · Synthekine will evaluate STK-012 in a Phase 1a/1b, open-label, multi-center, dose escalation study. The study will investigate STK-012 both as a monotherapy and in combination with an immune checkpoint inhibitor in individuals with advanced solid tumors. “IL-2 is a cytokine with proven benefit as an anti-cancer therapy. game of affectionWebAug 11, 2024 · The most similar approach to Medicenna’s comes from Synthekine, which is no surprise as the technology for both originated at Dr Chris Garcia’s lab at Stanford University. But Synthekine is shunning the gamma subunit and has instead created an alpha/beta-biased IL-2 agonist, STK-012, designed to avoid activation of NK cells. CD25 … black flat kitchen cabinetsgame of affection tagalogWebRegulatory T cell (Treg) therapies are efficacious in ameliorating GVHD but limited by variable suppressive capacities and the need for a high therapeutic dose. Here, we sought to expand Treg in vivo by expressing an orthogonal IL-2Rbeta receptor (oIL2Rbeta) that would selectively interact with orthogonal IL-2 (oIL2) cytokine and not wildtype IL2. black flat jellypop shoes for women